GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Simris Alg AB (OSTO:SIMRIS B) » Definitions » Cyclically Adjusted Price-to-FCF

Simris Alg AB (OSTO:SIMRIS B) Cyclically Adjusted Price-to-FCF : (As of Jun. 27, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Simris Alg AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Simris Alg AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Simris Alg AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simris Alg AB Cyclically Adjusted Price-to-FCF Chart

Simris Alg AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Simris Alg AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Simris Alg AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Simris Alg AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Simris Alg AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Simris Alg AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Simris Alg AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Simris Alg AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Simris Alg AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Simris Alg AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.013/132.8245*132.8245
=-0.013

Current CPI (Mar. 2025) = 132.8245.

Simris Alg AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -39.874 99.995 -52.965
201509 -7.183 100.228 -9.519
201512 -0.105 100.276 -0.139
201603 -0.243 100.751 -0.320
201606 -0.239 101.019 -0.314
201609 -0.126 101.138 -0.165
201612 -0.342 102.022 -0.445
201703 -0.249 102.022 -0.324
201706 -0.280 102.752 -0.362
201709 -0.318 103.279 -0.409
201712 -0.274 103.793 -0.351
201803 -0.265 103.962 -0.339
201806 -0.298 104.875 -0.377
201809 -0.142 105.679 -0.178
201812 -0.190 105.912 -0.238
201903 -0.213 105.886 -0.267
201906 -0.217 106.742 -0.270
201909 -0.327 107.214 -0.405
201912 0.001 107.766 0.001
202003 -0.183 106.563 -0.228
202006 -0.084 107.498 -0.104
202009 -0.029 107.635 -0.036
202012 -0.061 108.296 -0.075
202103 -0.063 108.360 -0.077
202106 -0.057 108.928 -0.070
202109 -0.045 110.338 -0.054
202112 -0.028 112.486 -0.033
202203 -0.040 114.825 -0.046
202206 -0.017 118.384 -0.019
202209 -0.033 122.296 -0.036
202212 -0.036 126.365 -0.038
202303 -0.037 127.042 -0.039
202306 -0.031 129.407 -0.032
202309 -0.032 130.224 -0.033
202312 -0.051 131.912 -0.051
202403 -0.016 132.205 -0.016
202406 -0.019 132.716 -0.019
202409 -0.013 132.304 -0.013
202412 -0.005 132.987 -0.005
202503 -0.013 132.825 -0.013

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Simris Alg AB  (OSTO:SIMRIS B) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Simris Alg AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Simris Alg AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Simris Alg AB Business Description

Industry
Traded in Other Exchanges
N/A
Address
Herrestadsvagen 24A, Hammenhog, SWE, 276 50
Simris Alg AB is a biotechnology company, engaged in research, development and production of bioactive substances from microalgae, for nutraceutical, cosmeceutical and pharmaceutical applications. The company's technology provides access to bioactive substances with novel functions, while replacing unsustainable raw materials from endangered marine species and ecosystems. Its first commercialised range is a series of omega-3 health supplements marketed under the company's own brand.

Simris Alg AB Headlines

No Headlines